search
Back to results

Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma (TACE-HAIC)

Primary Purpose

Hepatocellular Carcinoma, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy

Status
Recruiting
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Esketamine
Sufentanil
Sponsored by
The Second Affiliated Hospital of Chongqing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participate in this study and sign informed consent
  • Voluntarily receive postoperative intravenous controlled analgesia
  • Patients receiving TACE-HAIC treatment
  • HCC (hepatocellular carcinoma)patients with primary liver cancer BCLC(Barcelona Clinic Liver Cancer) stage B and C, liver function A
  • Age 18 to 80

Exclusion Criteria:

  • Patients who were unable to cooperate or refused to participate in the trial
  • Pregnant women
  • Patients with sensory abnormalities such as diabetes neuropathy
  • Patients with or having a history of serious mental disorders
  • Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic / diastolic blood pressure more than 180/100mg)
  • Patients with unstable angina pectoris or myocardial infarction within 6 months or congestive heart failure
  • Patients with intracranial hypertension or glaucoma
  • Patients with hyperthyroidism without treatment or insufficient treatment
  • Patients with severe respiratory dysfunction
  • Allergy or existing contraindication to chemotherapeutic drugs, opioids or ketamine drugs
  • Can not follow with the study procedure

Sites / Locations

  • The Second Affiliated Hospital, Chongqing Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Esketamine-PCIA(patient controlled intravenous analgesia)

Sufentanil-PCIA(patient controlled intravenous analgesia)

Arm Description

PCIA formula:100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.

PCIA formula:100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.

Outcomes

Primary Outcome Measures

Maximum pain intensity in the first 3 hours of HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 1 hour after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 2 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 3 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

Secondary Outcome Measures

Numbers of analgesic pump compressions
When the patients felt pain, the patient controlled analgesia pump can be pressed once
Analgesic consumption
Analgesic consumption is assessed by the total amount of pain remedy with dolantin when the analgesic effect is poor after pressing analgesic pump for 3 times or more
Pain intensity at 8 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 16 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 24 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 32 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 40 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity at 48 hours after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity on the seventh days after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity On the 14th day after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Pain intensity on the 21st after HAIC treatment
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)

Full Information

First Posted
May 20, 2022
Last Updated
February 22, 2023
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT05416073
Brief Title
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
Acronym
TACE-HAIC
Official Title
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma: a Prospective Study TACE-HAIC (Transcatheter Arterial Chemoembolization Combined With Hepatic Artery Infusion Chemotherapy )
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 22, 2022 (Actual)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Second Affiliated Hospital of Chongqing Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Previous studies have confirmed that limb pain caused by oxaliplatin chemotherapy is related to spinal cord central sensitization - induced hyperalgesia through oxaliplatin activating spinal cord NMDA receptor(N-methyl-D-aspartic acid receptor). The investigators speculate that this may be the same as the mechanism of severe abdominal pain caused by HAIC(Hepatic Artery Infusion Chemotherapy) during oxaliplatin infusion. The analgesic effect of Esketamine is mainly related to its inhibition of NMDA receptor in spinal cord. Therefore, this study hypothesized that Esketamine can inhibit the sensitization of spinal cord center by inhibiting NMDA receptor, so as to alleviate severe abdominal pain during HAIC perfusion, and reduce abdominal pain caused by ischemia and inflammation by TACE(transcatheter arterial chemoembolization) by improving organ perfusion and anti-inflammatory effect, Therefore, it is expected that Esketamine can better alleviate acute severe abdominal pain caused by TACE-HAIC (transcatheter arterial chemoembolization combined with Hepatic Artery Infusion Chemotherapy )treatment than sufentanil, decrease the dosage of opioids, and reduce the incidence and degree of chronic abdominal pain after treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy, Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Esketamine-PCIA(patient controlled intravenous analgesia)
Arm Type
Experimental
Arm Description
PCIA formula:100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.
Arm Title
Sufentanil-PCIA(patient controlled intravenous analgesia)
Arm Type
Active Comparator
Arm Description
PCIA formula:100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.
Intervention Type
Drug
Intervention Name(s)
Esketamine
Other Intervention Name(s)
patient controlled intravenous analgesia
Intervention Description
PCIA formula:100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Intervention Type
Drug
Intervention Name(s)
Sufentanil
Other Intervention Name(s)
patient controlled intravenous analgesia
Intervention Description
PCIA formula:100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Primary Outcome Measure Information:
Title
Maximum pain intensity in the first 3 hours of HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From the beginning of HAIC treatment to 3 hours after HAIC treatment
Title
Pain intensity at 1 hour after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From the beginning of HAIC treatment to 1 hour after HAIC treatment
Title
Pain intensity at 2 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 1 hour to 2 hours after HAIC treatment
Title
Pain intensity at 3 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 2 hours to 3 hours after HAIC treatment
Secondary Outcome Measure Information:
Title
Numbers of analgesic pump compressions
Description
When the patients felt pain, the patient controlled analgesia pump can be pressed once
Time Frame
From the beginning of HAIC treatment to 48 hours after HAIC treatment
Title
Analgesic consumption
Description
Analgesic consumption is assessed by the total amount of pain remedy with dolantin when the analgesic effect is poor after pressing analgesic pump for 3 times or more
Time Frame
From the beginning of HAIC treatment to 48 hours after HAIC treatment
Title
Pain intensity at 8 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 7 hours to 8 hours after HAIC treatment
Title
Pain intensity at 16 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 15 hours to 16 hours after HAIC treatment
Title
Pain intensity at 24 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 23 hours to 24 hours after HAIC treatment
Title
Pain intensity at 32 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 31 hours to 32 hours after HAIC treatment
Title
Pain intensity at 40 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 39 hours to 40 hours after HAIC treatment
Title
Pain intensity at 48 hours after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 47 hours to 48 hours after HAIC treatment
Title
Pain intensity on the seventh days after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 7 days to 8 days after HAIC treatment
Title
Pain intensity On the 14th day after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 13 days to 14 days after HAIC treatment
Title
Pain intensity on the 21st after HAIC treatment
Description
Pain intensity is assessed by numerical rating scale pain scores (0-10, 0 represents painless; 10 represents intolerable pain;higher scores mean a worse outcome)
Time Frame
From 20 days to 21 days after HAIC treatment
Other Pre-specified Outcome Measures:
Title
Ramsay Sedation score at 1 hour after HAIC treatment
Description
Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
Time Frame
From the beginning of HAIC treatment to 1 hour after HAIC treatment
Title
Ramsay Sedation score at 2 hours after HAIC treatment
Description
Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
Time Frame
From 1 hour to 2 hours after HAIC treatment
Title
Ramsay Sedation score at 3 hours after HAIC treatment
Description
Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
Time Frame
From 2 hours to 3 hours after HAIC treatment
Title
Ramsay Sedation score at 8 hours after HAIC treatment
Description
Ramsay Sedation score is assessed by: Grade 1 (soberness- the patient is anxious, uneasy or irritable)、 Grade 2 (soberness- the patient is cooperative, has good orientation or is quiet)、 Grade 3 (soberness- the patient only responds to commands)、 Grade 4 (sleep-the patient responds quickly to light tapping between eyebrows or strong sound stimulation)、 Grade 5 (sleep-the patient responds slowly to light tapping between the eyebrows or strong sound stimulation) and Grade 6 (sleep-the patient has no response to light tapping between eyebrows or strong sound stimulation). Grade 1 indicates no sedation ; Grade 2 and 3 indicate good sedation ; Grade 4 to 6 indicate poor sedation.
Time Frame
From 7 hours to 8 hours after HAIC treatment
Title
The quality of sleep on the fist day after HAIC treatment
Description
The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0~25 points indicate poor sleep quality;76~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome)
Time Frame
From the ending of HAIC treatment to 1 day after HAIC treatment
Title
The quality of sleep on the second day after HAIC treatment
Description
The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0~25 points indicate poor sleep quality;76~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome)
Time Frame
From 1 day to 2 days after HAIC treatment
Title
The quality of sleep on the third day after HAIC treatment
Description
The Richards-Campbell Sleep Questionnaire (RCSQ) is assessed by the quality of patients' sleep quality.0~25 points indicate poor sleep quality;76~100 points indicate good sleep quality (0-100, 0 represents the worst sleep quality; 100 represents the best sleep quality ;higher scores mean a better outcome)
Time Frame
From 2 days to 3 days after HAIC treatment
Title
Adverse reaction
Description
Adverse reaction is recorded according to follow-up visits after HAIC treatment
Time Frame
From the beginning of HAIC treatment to 72 hours after HAIC treatment
Title
Degree of satisfaction
Description
Degree of satisfaction is assessed by patient using numerical rating scale (0-10, 0 represents unsatisfactory; 10 represents complete satisfaction;higher scores mean a better outcome)
Time Frame
From the beginning of HAIC treatment to 24 hours after HAIC treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participate in this study and sign informed consent Voluntarily receive postoperative intravenous controlled analgesia Patients receiving TACE-HAIC treatment HCC (hepatocellular carcinoma)patients with primary liver cancer BCLC(Barcelona Clinic Liver Cancer) stage B and C, liver function A Age 18 to 80 Exclusion Criteria: Patients who were unable to cooperate or refused to participate in the trial Pregnant women Patients with sensory abnormalities such as diabetes neuropathy Patients with or having a history of serious mental disorders Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic / diastolic blood pressure more than 180/100mg) Patients with unstable angina pectoris or myocardial infarction within 6 months or congestive heart failure Patients with intracranial hypertension or glaucoma Patients with hyperthyroidism without treatment or insufficient treatment Patients with severe respiratory dysfunction Allergy or existing contraindication to chemotherapeutic drugs, opioids or ketamine drugs Can not follow with the study procedure
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Duan Guang you, MD
Phone
18323376014
Ext
+86
Email
duangy@hospital.cqmu.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
wang Da gang, MD
Phone
023 63693014
Ext
+86
Email
kuanrenlunli@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Huang He, MD
Organizational Affiliation
The Second Affiliated Hospital, Chongqing Medical University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Huang yan, MD
Organizational Affiliation
The Second Affiliated Hospital, Chongqing Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Second Affiliated Hospital, Chongqing Medical University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400010
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guangyou Duan, MD
Phone
(+86)18323376014
Email
duangy@hospital.cqmu.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The individual participant data for this study is available from the sponsor on reasonable request through email.
IPD Sharing Time Frame
Within one year

Learn more about this trial

Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma

We'll reach out to this number within 24 hrs